Posted by Michael Wonder on 31 May 2017
Kineret approved in Canada for the treatment of neonatal-onset multisystem inflammatory disease (NOMID)
30 May 2017 - Sobi Canada today announces that Health Canada has approved Kineret (anakinra) for the treatment of neonatal-onset multisystem inflammatory disease (NOMID) in adults, adolescents, children and infants aged eight months and older with a body weight of 10 kg or above.
Kineret is already approved in Canada for active rheumatoid arthritis in patients 18 years of age or older.
